key: cord-0803254-gq1puqox
authors: Mayer, Pierre; Saviano, Antonio; Kassegne, Loïc; Baumert, Thomas F.; Reimund, Jean-Marie; Habersetzer, François
title: Safe administration of corticosteroids in severe ulcerative colitis and active SARS-CoV2 infection
date: 2020-07-27
journal: Dig Liver Dis
DOI: 10.1016/j.dld.2020.07.022
sha: 7e54d925d0facc88e987b467ed816389bab61458
doc_id: 803254
cord_uid: gq1puqox

nan

Recently, we admitted a 20 year-old Somalian woman with UC diagnosed a year earlier, presenting a moderately severe UC flare with intense fatigue, abdominal pain and bloody diarrhoea. The patient was not on maintenance therapy because of a concurrent diagnosis of multidrug resistant miliary tuberculosis. At admission, the Lichtiger score was at 10. Laboratory analysis showed mild anemia and increased C-reactive protein ( Table 1) . A nasal swab for SARS-CoV2 was performed and resulted positive. Stool culture, C. Difficile toxin test and stool SARS-CoV2 RT-PCR were negative. A CT scan showed a pancolitis but no pulmonary lesions suggestive of COVID-19 pneumonia (Figure 1) .

Since systemic corticosteroids use in influenza patients has been associated with a significantly higher risk of lower respiratory tract infection and complications, we first decided to treat the patient with a combination of oral and rectal 5-aminosalicylic acid (4g/day p.o. and 1g/day locally). After 1 week, the patient did not improve and the Lichtiger score increased to 13. A flexible sigmoidoscopy showed a complete vascular pattern obliteration, multiple superficial ulcerations and pseudopolyps (UCEIS: 7/8). A nasal swab for SARS-CoV2 was repeated and resulted positive. As the patient was at low risk of developing a severe form of COVID-19 and her UC severity was worsening, we decided to start methylprednisolone 40 mg/day IV. The patient quickly improved at day 3 (Lichtiger score at 5) and did not develop any COVID-19 symptoms or complications. Laboratory parameters improved significantly ( Table 1) .

Acute severe ulcerative colitis is a life-threatening complication of UC and intravenous corticosteroids are the first-line therapy. Corticosteroids in IBD patients with SARS-CoV2 infection have been associated initially with worse outcomes 4 . However, in low-risk patients with asymptomatic SARS-CoV2 and acute severe UC, whether the risk associated with corticosteroids overweight the benefit is not clear. Recent data suggest a benefit of dexamethasone on the inflammatory state induced by COVID-19 in patients with respiratory failure 6 even though these results should still be taken with caution due to several study limitations such as the fact that at least 28% of participating patients were still hospitalized at the endpoint of the trial (day 28) 7 .

Taking into account risk factors of severe COVID-19 (in particular age) is probably essential before using corticosteroids. In the SECURE-IBD database, 50% of IBD patients who died from COVID-19 and 73% who died and/or needed hospitalisation in an intensive care unit and/or requested invasive ventilation were 60 years or older (respectively 28% and 31% for patient ≥ 80 years old; n=1696) 8 . In our experience, the use of corticosteroids in a young adult patient in the second week of SARS-CoV2 infection was safe and effective for treating an acute severe UC flare. 

Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study

Review article: prevention, diagnosis and management of COVID-19 in the IBD patient

COVID 19 and IBD WEBINARS and GUIDELINES | International Organization For the Study of Inflammatory Bowel Disease

but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: Results from an International Registry

A fatal case of COVID-19 pneumonia occurring in a patient with severe acute ulcerative colitis

Covid-19: Demand for dexamethasone surges as RECOVERY trial publishes preprint

SECURE-IBD Database PublicData

None.